|
|
|
Insider
Information: |
Kayyem Jon Faiz |
Relationship: |
|
City: |
San Diego |
State: |
CA |
|
|
Insider
Summary: |
|
|
|
Companies Owned : |
4 |
|
Direct
Shares |
375,074 |
|
Indirect Shares
|
10,693,978 |
|
|
Direct
Value |
$4,750,833 |
|
|
Indirect Value
|
$17,161,998 |
|
|
Total
Shares |
11,069,052 |
|
|
Total
Value |
$21,912,830 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
Total
Filings :
|
0
|
0
|
Stock
price went up :
|
0
|
0
|
Stock
price went down : |
0
|
0
|
|
|
|
Gain/Loss Ratio : |
0.0
|
0.0
|
Percentage
Gain/Loss : |
0.0%
|
0.0%
|
|
|
|
|
|
|
Holdings
:
Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold |
|
Aeolus Pharmaceuticals Inc |
AOLS |
10% Owner |
|
0 |
2006-06-05 |
9,800,000 |
Premium* |
|
Genmark Diagnostics, Inc. |
GNMK |
SVP, Research & Develo... |
2018-02-02 |
197,622 |
2018-02-02 |
713,893 |
Premium* |
|
Inhibrx, Inc. |
INBX |
Director |
2022-08-02 |
0 |
2024-05-30 |
0 |
Premium* |
|
Biodesix Inc |
BDSX |
|
2023-08-03 |
177,452 |
2023-08-03 |
180,085 |
Premium* |
|
|
|
|
|
|
|
|
|
|
Records found :
91 |
Free Registration Required For Full Results. Limit: 25
|
|
Download |
Page 4 of 4
|
Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
GNMK |
Genmark Diagnostics, Inc. |
SVP, Research & Development |
|
2014-03-04 |
4 |
AS |
$12.47 |
$88,453 |
D/D |
(7,095) |
99,060 |
0 |
- |
|
GNMK |
Genmark Diagnostics, Inc. |
SVP, Research & Development |
|
2017-01-19 |
4 |
S |
$12.47 |
$71,303 |
D/D |
(5,718) |
159,460 |
0 |
- |
|
GNMK |
Genmark Diagnostics, Inc. |
SVP, Research & Development |
|
2014-12-15 |
4 |
AS |
$12.51 |
$4,066 |
D/D |
(325) |
108,448 |
0 |
- |
|
GNMK |
Genmark Diagnostics, Inc. |
SVP, Research & Development |
|
2017-05-19 |
4 |
S |
$12.89 |
$16,306 |
D/D |
(1,265) |
200,989 |
0 |
- |
|
GNMK |
Genmark Diagnostics, Inc. |
SVP, Research & Development |
|
2017-06-02 |
4 |
S |
$12.89 |
$1,701 |
D/D |
(132) |
200,857 |
0 |
- |
|
GNMK |
Genmark Diagnostics, Inc. |
Chief Scientific Officer |
|
2013-04-01 |
4 |
AS |
$12.93 |
$77,580 |
I/I |
(6,000) |
118,934 |
0 |
- |
|
GNMK |
Genmark Diagnostics, Inc. |
SVP, Research & Development |
|
2014-01-02 |
4 |
AS |
$13.18 |
$1,397,080 |
I/I |
(106,000) |
619,308 |
0 |
- |
|
GNMK |
Genmark Diagnostics, Inc. |
SVP, Research & Development |
|
2017-05-02 |
4 |
S |
$13.34 |
$1,774 |
D/D |
(133) |
202,254 |
0 |
- |
|
GNMK |
Genmark Diagnostics, Inc. |
SVP, Research & Development |
|
2014-07-01 |
4 |
AS |
$13.60 |
$81,600 |
I/I |
(6,000) |
88,934 |
0 |
- |
|
GNMK |
Genmark Diagnostics, Inc. |
SVP, Research & Development |
|
2014-01-15 |
4 |
AS |
$14.00 |
$147,266 |
I/I |
(10,519) |
608,789 |
0 |
- |
|
GNMK |
Genmark Diagnostics, Inc. |
SVP, Research & Development |
|
2014-01-16 |
4 |
AS |
$14.06 |
$555,103 |
I/I |
(39,481) |
569,308 |
0 |
- |
|
INBX |
Inhibrx, Inc. |
Director |
|
2023-01-23 |
4 |
AS |
$25.26 |
$239,999 |
I/I |
(9,500) |
3,224,301 |
0 |
- |
|
INBX |
Inhibrx, Inc. |
Director |
|
2022-12-21 |
4 |
AS |
$26.87 |
$256,679 |
I/I |
(9,500) |
3,233,801 |
0 |
- |
|
INBX |
Inhibrx, Inc. |
Director |
|
2022-11-21 |
4 |
AS |
$29.33 |
$283,972 |
I/I |
(9,500) |
3,243,301 |
0 |
- |
|
INBX |
Inhibrx, Inc. |
Director |
|
2022-10-21 |
4 |
AS |
$29.39 |
$286,232 |
I/I |
(9,500) |
3,252,801 |
0 |
- |
|
INBX |
Inhibrx, Inc. |
Director |
|
2024-05-30 |
4 |
D |
$30.00 |
$98,229,030 |
I/I |
(3,274,301) |
0 |
0 |
- |
|
91 Records found
|
|
Page 4 of 4 |
|
Free Registration Required For Full Results. Limit: 25
|
|
|
Transaction Code Key: |
Ownership Code Key |
|
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
|
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
|
IO |
- Initital Ownership |
D |
- Disposed |
|
|
|
|
|
|